Stay updated on Nivolumab vs Docetaxel in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Docetaxel in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Docetaxel in Lung Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the context of a study comparing the overall survival of BMS-936558 (Nivolumab) with Docetaxel in subjects with non-squamous cell non-small cell lung cancer after failure of prior platinum-based chemotherapy.
    Difference
    0.1%
    Check dated 2024-06-06T16:03:27.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    18 days ago
    Change Detected
    Summary
    The change on the webpage possibly concerns a shift in the participation criteria from Collaborators to Researchers looking for individuals who meet specific eligibility criteria related to non-squamous cell NSCLC, indicating a focus on medical and healthcare-related research.
    Difference
    17%
    Check dated 2024-05-22T10:41:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:51:44.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Docetaxel in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Docetaxel in Lung Cancer Clinical Trial page.